Michael J. Meehan, Esq

Moderator and Author of Case Study 2
Claudia R. Adkison, JD, PhD
Executive Associate Dean, Administration and Faculty Affairs, Emory University School of Medicine, Atlanta, GA

Author of Case Study 1
Michael J. Meehan, Esq
Senior Counsel and Corporate Assistant Secretary, Cleveland Clinic, Cleveland, OH

Panelists
Gail H. Cassell, PhD, DSc (hon)
Vice President, Scientific Affairs, and Distinguished Lilly Research Scholar for Infectious Diseases, Eli Lilly and Company, Indianapolis, IN

Jeffrey P. Kahn, PhD, MPH
Maas Family Chair in Bioethics and Director, Center for Bioethics, University of Minnesota, Minneapolis, MN

Philip A. Pizzo, MD
Dean and Professor of Pediatrics and of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA

Thomas P. Stossel, MD
Professor of Medicine, Harvard Medical School, Boston, MA

Dr. Cassell reported that she receives a salary, grant/research support, and stock options through her employment with Eli Lilly and Company.

Dr. Stossel reported that he has ownership interests in ZymeQuest, Inc., and in Critical Biologics Corp.; has intellectual property rights in Critical Biologics Corp.; has received consulting/advisory fees from Merck, Inc.; has received honoraria from Pfizer, Inc.; and has received royalties from Lippincott Williams & Wilkins.

All other participants reported that they have no financial interests, relationships, or affiliations that pose a potential conflict of interest with this article.

Moderator and Author of Case Study 2
Claudia R. Adkison, JD, PhD
Executive Associate Dean, Administration and Faculty Affairs, Emory University School of Medicine, Atlanta, GA

Author of Case Study 1
Michael J. Meehan, Esq
Senior Counsel and Corporate Assistant Secretary, Cleveland Clinic, Cleveland, OH

Panelists
Gail H. Cassell, PhD, DSc (hon)
Vice President, Scientific Affairs, and Distinguished Lilly Research Scholar for Infectious Diseases, Eli Lilly and Company, Indianapolis, IN

Jeffrey P. Kahn, PhD, MPH
Maas Family Chair in Bioethics and Director, Center for Bioethics, University of Minnesota, Minneapolis, MN

Philip A. Pizzo, MD
Dean and Professor of Pediatrics and of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA

Thomas P. Stossel, MD
Professor of Medicine, Harvard Medical School, Boston, MA

Dr. Cassell reported that she receives a salary, grant/research support, and stock options through her employment with Eli Lilly and Company.

Dr. Stossel reported that he has ownership interests in ZymeQuest, Inc., and in Critical Biologics Corp.; has intellectual property rights in Critical Biologics Corp.; has received consulting/advisory fees from Merck, Inc.; has received honoraria from Pfizer, Inc.; and has received royalties from Lippincott Williams & Wilkins.

All other participants reported that they have no financial interests, relationships, or affiliations that pose a potential conflict of interest with this article.

Moderator and Author of Case Study 2
Claudia R. Adkison, JD, PhD
Executive Associate Dean, Administration and Faculty Affairs, Emory University School of Medicine, Atlanta, GA

Author of Case Study 1
Michael J. Meehan, Esq
Senior Counsel and Corporate Assistant Secretary, Cleveland Clinic, Cleveland, OH

Panelists
Gail H. Cassell, PhD, DSc (hon)
Vice President, Scientific Affairs, and Distinguished Lilly Research Scholar for Infectious Diseases, Eli Lilly and Company, Indianapolis, IN

Jeffrey P. Kahn, PhD, MPH
Maas Family Chair in Bioethics and Director, Center for Bioethics, University of Minnesota, Minneapolis, MN

Philip A. Pizzo, MD
Dean and Professor of Pediatrics and of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA

Thomas P. Stossel, MD
Professor of Medicine, Harvard Medical School, Boston, MA

Dr. Cassell reported that she receives a salary, grant/research support, and stock options through her employment with Eli Lilly and Company.

Dr. Stossel reported that he has ownership interests in ZymeQuest, Inc., and in Critical Biologics Corp.; has intellectual property rights in Critical Biologics Corp.; has received consulting/advisory fees from Merck, Inc.; has received honoraria from Pfizer, Inc.; and has received royalties from Lippincott Williams & Wilkins.

All other participants reported that they have no financial interests, relationships, or affiliations that pose a potential conflict of interest with this article.